

Study of clinical utility of prostate cancer test, 7/17

July 2017—MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association annual meeting in Boston.

In the study of 211 African American men, the test successfully identified men with false-negative biopsy results. Upon repeat biopsy, 38 percent of patients were diagnosed with prostate cancer, of which 33 percent were diagnosed with clinically significant disease (Gleason score >7). When the test was negative, it yielded a 96 percent negative predictive value for aggressive prostate cancer.

[**MDxHealth**](#), 866-259-5644